GSK: Blenrep Combinations Accepted for Review by the U.S. FDA for the Treatment of Relapsed/refractory Multiple Myeloma
November 26, 2024
November 26, 2024
LONDON, England, Nov. 26 (TNSres) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Nov. 25, 2024:
* * *
- Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy, including overall survival in DREAMM-7
- If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma trea . . .
* * *
- Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy, including overall survival in DREAMM-7
- If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma trea . . .